{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:51:17Z","timestamp":1781895077135,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"DOI":"10.7759\/cureus.111161","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:57:12Z","timestamp":1781891832000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Functional and Anatomical Outcomes of Intravitreal Faricimab in Suboptimal Responders With Neovascular Age-Related Macular Degeneration: A 24-Month Clinical Audit"],"prefix":"10.7759","author":[{"given":"Dhanya","family":"Sukumaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delicia","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Naved","family":"Abdul Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Amankwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prema","family":"Maharajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Mubashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambreen","family":"Sarmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Dhar-Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier JS","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022, 399:729-40. 10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani AM","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al.. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024, 131:914-26. 10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"ref3","unstructured":"Faricimab for treating wet age-related macular degeneration. (2022). Accessed. May 18, 2026: https:\/\/www.nice.org.uk\/guidance\/ta800."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-04059-8","article-title":"Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study","volume":"39","author":"Peto T","year":"2025","unstructured":"Peto T, Pearce I, Talks J, et al.. Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study. Eye (Lond). 2025, 39:3350-8. 10.1038\/s41433-025-04059-8","journal-title":"Eye (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.07.020","article-title":"Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab","volume":"9","author":"Sim SY","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, et al.. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2025, 9:22-30. 10.1016\/j.oret.2024.07.020","journal-title":"Ophthalmol Retina"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/life14020193","article-title":"Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration","volume":"14","author":"Ng B","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, et al.. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life (Basel). 2024, 14:193. 10.3390\/life14020193","journal-title":"Life (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit SA","year":"2024","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, et al.. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024, 8:360-6. 10.1016\/j.oret.2023.10.018","journal-title":"Ophthalmol Retina"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100744","article-title":"Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a scoping review","volume":"5","author":"Chaudhary V","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP. Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a scoping review. Ophthalmol Sci. 2025, 5:100744. 10.1016\/j.xops.2025.100744","journal-title":"Ophthalmol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03223-w","article-title":"Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists","volume":"38","author":"Downey L","year":"2024","unstructured":"Downey L, Sivaprasad S, Chhabra R, et al.. Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists. Eye (Lond). 2024, 38:3077-86. 10.1038\/s41433-024-03223-w","journal-title":"Eye (Lond)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001702","article-title":"Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis","volume":"9","author":"Samac\u00e1-Samac\u00e1 D","year":"2024","unstructured":"Samac\u00e1-Samac\u00e1 D, Hern\u00e1ndez-Castillo C, Prieto-Pinto L, et al.. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. BMJ Open Ophthalmol. 2024, 9:001702. 10.1136\/bmjophth-2024-001702","journal-title":"BMJ Open Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00753-6","article-title":"Efficacy, durability and safety of faricimab in neovascular age-related macular degeneration and diabetic macular oedema: lessons learned from registration trials","volume":"12","author":"Larsen HO","year":"2023","unstructured":"Larsen HO, Grauslund J, Vergmann AS. Efficacy, durability and safety of faricimab in neovascular age-related macular degeneration and diabetic macular oedema: lessons learned from registration trials. Ophthalmol Ther. 2023, 12:2253-64. 10.1007\/s40123-023-00753-6","journal-title":"Ophthalmol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire MG","year":"2016","unstructured":"Maguire MG, Martin DF, Ying GS, et al.. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016, 123:1751-61. 10.1016\/j.ophtha.2016.03.045","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49\u2009485 eyes","volume":"4","author":"Ciulla TA","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49\u2009485 eyes. Ophthalmol Retina. 2020, 4:19-30. 10.1016\/j.oret.2019.05.017","journal-title":"Ophthalmol Retina"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley M","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022, 82:825-30. 10.1007\/s40265-022-01713-3","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S591029","article-title":"Real-world outcomes of switching to faricimab in treatment-experienced and resistant neovascular age-related macular degeneration: a single-centre retrospective study","volume":"20","author":"Stewart C","year":"2026","unstructured":"Stewart C, Bhangu JS, Swarnkar PK, et al.. Real-world outcomes of switching to faricimab in treatment-experienced and resistant neovascular age-related macular degeneration: a single-centre retrospective study. Clin Ophthalmol. 2026, 20:591029. 10.2147\/OPTH.S591029","journal-title":"Clin Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498777-real-world-functional-and-anatomical-outcomes-of-intravitreal-faricimab-in-suboptimal-responders-with-neovascular-age-related-macular-degeneration-a-24-month-clinical-audit","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:57:16Z","timestamp":1781891836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498777-real-world-functional-and-anatomical-outcomes-of-intravitreal-faricimab-in-suboptimal-responders-with-neovascular-age-related-macular-degeneration-a-24-month-clinical-audit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.111161","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}